Curavit Clinical Research is a Boston-based, all-virtual Contract Research Organization (CRO) that designs and runs decentralized clinical trials. Through its Virtual Clinical Site and STRATUS platform, Curavit recruits, enrolls, and monitors diverse patient populations remotely - eliminating physical site infrastructure and travel while improving data quality. The company specializes in trials for digital therapeutics (DTx) and partners with sponsors and existing CROs to fix the execution layer of clinical research, accelerating timelines and lowering costs.
Joel Morse is the co-founder and CEO of Curavit Clinical Research, a virtual contract research organization (VCRO) that designs and runs decentralized clinical trials for digital therapeutics, devices and drugs. A mechanical engineer turned serial healthcare operator, he previously co-founded C3i Solutions in 1993 and built it into a global leader in tech-enabled clinical trial services before selling to Telerx in 2014. At Curavit he is betting that trials can be run where patients actually live, stitching together wearables, web recruitment and real-world evidence to reach people traditional sites never see.